Article in Japanese

Estimation of the medical cost of mumps between the fiscal year 2011 and 2019 and cost-effectiveness of the 2-dose regimen of mumps vaccination under the National Immunization Program

Takayori ONO^1）, Fumie TOKUDA^2）, Kyoko MURAKAMI^1）, Mihoko OTA^2）, Hideaki KUMIHASHI^1）, Naoko NISHIMURA^3）

Medical expenses from mumps infection were calculated using the insurer database (JMDC Claims Database). Cost-effectiveness of the 2-dose mumps vaccination, under the National Immunization Program, was analyzed from the results of vaccination coverage, incidence of post-vaccination mumps and adverse reactions, cited from previous studies on a single vaccination. Costs of vaccination were cited from public material, and costeffectiveness was analyzed as the incremental benefit-cost ratio (IBCR) by using the outcome of cost-effectiveness assessments. There were no major changes in the expenses for outpatient and inpatient visits for mumps between the fiscal year 2011 and 2019. The IBCR was ≥ 1 (1.40 to 1.68) when analyzed from a social viewpoint, and costeffectiveness was confirmed as higher than the costs of 2-dose vaccine when administered as routine vaccinations, as analyzed from a social perspective similarly to a previous research.

---

1）Global Vaccine Business Unit, Takeda Pharmaceutical Corporation Limited
2）Japan Medical Office, Takeda Pharmaceutical Corporation Limited
3）Departments of Pediatrics, Konan Kosei Hospital

Key words	mumps, mumps vaccine, cost-effectiveness, routine vaccination, two doses of mumps vaccine
Received	August 9, 2022
Accepted	March 9, 2023

35 (2)：107─119,2023